Merck price target lowered to $82 from $89 at BMO Capital

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the shares after its Q1 results and FY25 guidance cut. The firm warns that further Gardasil headwinds complicate Merck’s potential to regain its footing, adding that while the FDA labeling changes are unlikely, ACIP recommendation changes could meaningfully negatively impact long-term U.S. revenue, the analyst tells investors in a research note.